GlaxoSmithKline plc operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares GlaxoSmithKline plc with three other
companies in this sector in UNITED STATES :
sales of $45.80 billion
of which 100%
was pharmaceutical products),
of which 69%
was Pharmaceuticals), and
Bristol-Myers Squibb Company
of which 28%
was Prioritized Brands-Revlimid).
During the year ended December of 2020, sales at
GlaxoSmithKline plc were $44.07 billion.
increase of 2.1%
versus 2019, when the company's sales were $43.18 billion.
This was the fifth consecutive year of sales increases at GlaxoSmithKline plc
(and since 2015, sales have increased a total of 21%).
Sales of Consumer Healthcare saw an increase
that was more than double the company's growth rate: sales were up
12.7% in 2020, from
$11.51 billion to $12.97 billion.
Not all segments of GlaxoSmithKline plc experienced an increase in sales in 2020:
sales of Unallocated fell 41.1% to $36.19 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
GlaxoSmithKline plc also experienced decreases in sales in
Pharmaceuticals (down 1.8% to $22.04 billion)
Vaccines (down 1.4% to $9.02 billion)